Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16153758 | 1.00 | ANPEP (0.67) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL859527 | 0.98 | ANPEP (0.69) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL16155879 | 0.98 | ANPEP (0.69) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL902633 | 0.84 | EPHX1 (0.80) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL15476621 | 0.84 | EPHX1 (0.80) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL902607 | 0.84 | EPHX1 (0.80) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL2736189 | 0.84 | EPHX1 (0.80) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL18034347 | 0.84 | EPHX1 (0.80) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL16279669 | 0.82 | EPHX1 (0.76) | ANPEPEPHX1SLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL16279671 | 0.82 | EPHX1 (0.76) | ANPEPEPHX1SLC6A2TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865755-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-8569351-B2 | Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130096162-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-04-18 | — | — | US | disclosed |
| US-8394846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8338418-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ANPEP 137/4885EPHX1 994/4885SLC6A2 201/4885 |
| US-20130096162-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | ANPEP 127/4885EPHX1 730/4885SLC6A2 244/4885 |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ANPEP 117/4885EPHX1 752/4885SLC6A2 250/4885 |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ANPEP 117/4885EPHX1 752/4885SLC6A2 250/4885 |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ANPEP 137/4885EPHX1 994/4885SLC6A2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.